335 reports of this reaction
2.4% of all FONDAPARINUX SODIUM reports
#6 most reported adverse reaction
HAEMOGLOBIN DECREASED is the #6 most commonly reported adverse reaction for FONDAPARINUX SODIUM, manufactured by Mylan Institutional LLC. There are 335 FDA adverse event reports linking FONDAPARINUX SODIUM to HAEMOGLOBIN DECREASED. This represents approximately 2.4% of all 13,905 adverse event reports for this drug.
Patients taking FONDAPARINUX SODIUM who experience haemoglobin decreased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HAEMOGLOBIN DECREASED is a less commonly reported adverse event for FONDAPARINUX SODIUM, but still significant enough to appear in the safety profile.
In addition to haemoglobin decreased, the following adverse reactions have been reported for FONDAPARINUX SODIUM:
The following drugs have also been linked to haemoglobin decreased in FDA adverse event reports:
HAEMOGLOBIN DECREASED has been reported as an adverse event in 335 FDA reports for FONDAPARINUX SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
HAEMOGLOBIN DECREASED accounts for approximately 2.4% of all adverse event reports for FONDAPARINUX SODIUM, making it a notable side effect.
If you experience haemoglobin decreased while taking FONDAPARINUX SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.